Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 310 matching trials from the live ClinicalTrials.gov search.

Filters: "ALK" Clear all

Conditions: Bioequivalency
Interventions: Ensartinib Hydrochloride; Drug
Lead sponsor: Xcovery Holdings, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 158
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
Interventions: Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson Disease
Interventions: Cannabidiol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
Interventions: Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Year to 21 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2035
U.S. locations: 10
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2); Biological · Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Infant-Type Hemispheric Glioma
Interventions: Alectinib, Entrectinib, Surgery, Cyclophosphamide, Etoposide, Carboplatin, Filgrastim, Pegfilgrastim; Drug · Procedure · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 60 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: NSCLC
Interventions: Online Survey; Other
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • San Carlos, California

Conditions: Non-small Cell Lung Cancer
Interventions: M7824, Pembrolizumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 25
States / cities: Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Fatty Liver
Interventions: Group 1 NRPT, Group 2 NRPT, Group 3 Placebo; Dietary Supplement · Other
Lead sponsor: Elysium Health; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Hialeah, Florida • Lake Worth, Florida • Miami, Florida + 5 more

Conditions: NSCLC
Interventions: Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection; Device · Drug · Other
Lead sponsor: Galvanize Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Non-Small-Cell Lung Carcinoma NSCLC
Interventions: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ceritinib, Pemetrexed, Docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 13
States / cities: Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more

Conditions: ALK-activated Tumors
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions: Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Maynard, Massachusetts

Conditions: Allergy
Interventions: Grazax; Drug
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Schizophrenia
Interventions: ALKS 3831; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio

Conditions: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
Interventions: TRI-611; Drug
Lead sponsor: TRIANA Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 10 more

Conditions: Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Xanthogranuloma Family (XG), Indeterminate Dendritic Cell Histiocytosis, Malignant Histiocytic Neoplasm (MHN), ALK-positive Histiocytosis, Mixed Histiocytosis (MXH), Multicentric Reticulohistiocytoma (MRH), Necrobiotic Xanthogranuloma (NX)
Interventions: Registry study; Other
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 3 more

Conditions: Advanced Lung Cancer
Interventions: Ganetespib (STA-9090) and crizotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions: Alintegimod, Ipilimumab, Nivolumab; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more

Conditions: Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS, Solid Tumor, B-Cell Lymphoma
Interventions: ASP3026; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: Orange, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Lung Cancer
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

Epidemiology of Young Lung Cancer - Survey

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

A Trial of Grazax in Subjects With Hayfever

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

A Phase 1 Safety Study in Adults With Schizophrenia

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

International Rare Histiocytic Disorders Registry (IRHDR)

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Study of Tumor Samples From Patients With Lung Cancer